Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus standard chemotherapy in unresectable malignant mesothelioma (Phase II, single-arm)
ChiCTR2200060395Phase 2Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig in mesothelioma, sponsored by Jilin Provincial Cancer Hospital. Primary endpoints: Objective response rate (ORR) and Incidence and severity of treatment-related adverse events. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
pumitamig
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ChiCTR2200060395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060395.